{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.3","upperLimit":"13.4","value":"10.2"},{"groupId":"OG001","lowerLimit":"4.6","upperLimit":"6.4","value":"4.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"238"},{"groupId":"OG001","value":"234"}],"units":"Participants"}],"description":"Time to relapse was defined as the interval (in months) from the date of randomization to the date of documented relapse. Estimates of relapse rate were based on the cumulative incidence function from a competing risk analysis with death as a competing risk for relapse from complete remission (CR)/ complete remission with incomplete blood count recovery (CRi). Documented relapse was defined as, the earliest date of the following: • ≥ 5% bone marrow blasts (myeloblasts) from Central Pathology report, or • appearance of \\> 0% blasts in the peripheral blood with a later bone marrow confirmation (bone marrow blast \\[myeloblasts\\] ≥ 5%) within 100 days, or • at least 2 peripheral blasts ≥ 5% within 30 days.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 300 mg azacitidine tablets once a day (QD) for the first 14 days of each 28-day treatment cycle until discontinuation, which includes the following reasons: disease relapse, withdrawal of consent, adverse events, participant became eligible for allogeneic bone marrow or stem cell transplantation during the treatment period, death, lost to follow-up, or protocol violation or until the end of the study.","id":"OG000","title":"Oral Azacitidine Plus Best Supportive Care"},{"description":"Participants received identically matching placebo tablets QD for the first 14 days of each 28-day treatment cycle until no longer receiving benefit, withdrawal of consent, disease relapse, adverse events, participant became eligible for allogeneic bone marrow or stem cell transplantation during the treatment period, lost to follow-up, or protocol violation or until the end of the study.","id":"OG001","title":"Placebo Plus Best Supportive Care"}],"paramType":"MEDIAN","populationDescription":"The intent to treat population includes participants who were randomized, regardless of whether they received treatment or not.","reportingStatus":"POSTED","timeFrame":"From day 1 (randomization) up to data cut off date of 06 August 2024; approximately 135.5 months","title":"Kaplan-Meier Estimate of Time to Relapse","type":"SECONDARY","unitOfMeasure":"months"}